Formosa Pharmaceuticals Submits Clinical Trial Application for Breast Cancer Drug

The company has filed regulatory paperwork for TSY-110, an antibody-drug conjugate biosimilar designed specifically to target HER2-positive breast cancers.

28 Aug, 12:03 — 28 Aug, 12:03

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual4d ago

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers - Taiwan News

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers Taiwan News

Read full article →

Formosa Pharmaceuticals Submits Clinical Trial Application for Breast Cancer Drug

Sources

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers - Taiwan News

Related Stories

China’s Solar Power Capacity Surpasses Coal for First Time

Apple and OpenAI Trade Accusations in Escalating Trade Secrets Lawsuit

Trump Pushes Tech Firms to Rename Lake Ontario as 'Lake America' on Maps

Russia’s Domestic Satellite Internet System Fails to Reach Target Orbit